Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 1:41 PM
Ignite Modification Date: 2025-12-24 @ 1:41 PM
NCT ID: NCT05393895
Description: None
Frequency Threshold: 5
Time Frame: Adverse events were collected over a period of at least 6 weeks and up to 21 weeks for the last participants exiting the study.
Study: NCT05393895
Study Brief: An Evaluation of the Safety of CSF-1 in Presbyopic Subjects
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
CSF-1 One drop bilaterally twice daily for at least 6 weeks CSF-1: One drop bilaterally twice daily for at least 6 weeks 0 None 0 118 21 118 View
Vehicle One drop bilaterally twice daily for at least 6 weeks Vehicle: One drop bilaterally twice daily for at least 6 weeks 0 None 0 60 15 60 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Conjunctival hyperaemia SYSTEMATIC_ASSESSMENT Eye disorders MedDRA 23.1 View
Conjuctival papillae SYSTEMATIC_ASSESSMENT Eye disorders MedDRA 23.1 View
Vision blurred SYSTEMATIC_ASSESSMENT Eye disorders MedDRA 23.1 View
Instillation site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA 23.1 View
COVID-19 SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA 23.1 View